Table 2.

Individual characteristics at participation

ID	Age at participation, y	Combined oral contraceptive washout, wk	Dopamine agonist, wk	Prolactin at screening, ng/mL	Prolactin at visit 1, ng/mL	Prolactin at visit 2, ng/mL	Progesterone at visit 1, ng/mL	Progesterone at visit 2, ng/mL
1a	40	9.7	2.0	19.4	28.4	29.8	2.09	3.15
2	38	7.7b	n/a	61.2	24.6	34.3	0.20	11.3
3a	41	n/a	2.1	41.5	51.6	44.5	4.94	0.40
4a	44	n/a	2.6	40.5	57.8	54.9	2.92	1.15
5a	39	n/a	3.6	21.5	34.9	35.3	6.09	6.58
6a	36	n/a	14.7b,c	331.5	150d	150d	0.25	0.29
7	23	n/a	17b,c	37.5	34.1	35.0	0.39	0.45
8a	24	10.3	6.6	< 1.0	24.8	24.9	9.19	9.25
9	35	n/a	n/a	50.6	63.3	61.2	0.44	0.20
10a	24	n/a	n/a	34.6	77.2	75.9	8.64	6.78
11a	30	8.9	n/a	36.9	27.0	28.2	1.00	0.31

Data gathered from documentation in each participant’s study file. Age at participation was calculated using the date of visit 1. Length of washout was calculated by subtracting start date of washout from date of visit 1. Prolactin at visit 1 includes the mean value from all study pools from visit 1. Prolactin at visit 2 includes the mean value from study pools that were collected during kisspeptin administration (hour 1-hour 11).

Abbreviations: ID, identification; n/a, individuals who were not taking these types of medication and therefore did not undergo washout.

^a Pulse occurred within 30 minutes of first kisspeptin administration.

^b The last day of the month was used as the start date of washout as only the month was recorded for start date of washout.

^c Participants began their washout before screening visit as part of their clinical care.

^d This sample returned value above the limit of detection (upper range 150 ng/mL was recorded for this individual).